ASCO’s Center for Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct surveys of ASCO members for research purposes.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
A new study in the Journal of Oncology Practice (JOP) finds that while primary care physicians (PCPs) are often involved in cancer survivorship care, many do not feel adequately prepared for key components of it.
Positive findings from fully enrolled cohorts in non-small cell lung cancer and metastatic breast cancer from ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR™) Study will be presented in poster sessions at the 2019 ASCO® Annual Meeting. In addition, the study is being expanded to include patients with active brain metastases and three new drug therapies. Pharmaceutical company Boehringer Ingelheim has also joined the study and, later this year, will provide afatinib (Gilotrif®) to participants who enroll in a tissue-agnostic cohort of patients with an NRG1 gene fusion. That same month, the TAPUR Study also will add two new drugs from existing pharmaceutical company collaborators: abemaciclib (Verzenio®, Eli Lilly and Company) and talazoparib (Talzenna®, Pfizer).
ASCO members are encouraged to use the ACT Network to tell their representatives in Congress to support the CLINICAL TREATMENT Act and protect patient access to clinical trials.
A new study published today in the Journal of Oncology Practice (JOP) reveals the findings of a 2018 ASCO Oncology Workforce survey on oncologists’ perceptions and practice behaviors related to diet, physical activity, and weight management in people with cancer — during and after active treatment.
ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
ASCO and Friends of Cancer Research have commended the U.S. Food and Drug Administration on four recently released draft guidance documents related to expanding clinical trial eligibility in a joint letter to Acting Commissioner Ned Sharpless, MD.
Early registration is now open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician investigators and research staff from across the country for two days of learning and collaboration. The meeting offers colleagues from a variety of types of research programs a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.
ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.
ASCO joined the Alliance for Childhood Cancer on Capitol Hill for the 8th Annual Childhood Cancer Action Day, where advocates met directly with Members of Congress and their staff about cancer policy priorities related to pediatric cancer.
During the Action Day, advocates urged Members of Congress to:
Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from the American Society of Clinical Oncology, Inc.’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR™) Study were presented in poster sessions during the American Association for Cancer Research (AACR) Annual Meeting 2019. In addition, all seven pharmaceutical companies currently participating in the TAPUR Study have recently renewed their commitment to support it and provide study drugs at no cost for an additional one to three years.
Today, ASCO is kicking off its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft FY 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
ASCO joined hundreds of other patient groups, scientific societies, and research and health care institutions in urging members of Congress to increase federal funding for cancer research and prevention in the Fiscal Year (FY) 2020 funding bill.
The Workshop on Development of Tissue-Agnostic, Biomarker-Based Indications, cohosted by ASCO, the Food and Drug Administration (FDA), and Friends of Cancer Research, is now open for registration. The April 26 full-day event will take place at the FDA White Oak Campus in Silver Spring, Maryland.
Two of the world’s leading cancer organizations have released national strategies for meeting the needs of the growing population of cancer survivors in the United States while addressing provider shortages and rising costs. ASCO and the American Cancer Society convened a summit in January of 2018 focused on developing and implementing care that addresses these issues by treating patients in personalized follow-up care pathways depending on the type and level of resources needed for their long-term care. The strategies from that summit were published on March 8, in CA: A Cancer Journal for Clinicians.